The European Medicines Agency (EMA) said on Thursday it had recommended GlaxoSmithKline's antibody-based medicine Xevudy for the treatment of the coronavirus disease
MOSCOW (Pakistan Point News / Sputnik - 16th December, 2021) The European Medicines Agency (EMA) said on Thursday it had recommended GlaxoSmithKline's antibody-based medicine Xevudy for the treatment of the coronavirus disease.
"EMA's human medicines committee (CHMP) has recommended authorising the monoclonal antibody Xevudy (sotrovimab) for the treatment of COVID-19. The applicant is GlaxoSmithKline Trading Services Limited, who developed the medicine together with Vir Biotechnology," the statement says.
Xevudy may be used for treating COVID-19 in persons from 12 years of age and weighing from 40 kilograms (88 Pounds) with mild symptoms, the EMA added.
